HP 501
Alternative Names: HP-501Latest Information Update: 11 Jul 2023
At a glance
- Originator Hinova pharmaceuticals
- Class Antigouts; Small molecules
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Gout; Hyperuricaemia
- Preclinical Kidney disorders
Most Recent Events
- 10 Jul 2023 Preclinical trials in Gout (Combination therapy) in USA, China (PO) (Hinova Pharmaceuticals, pipeline July 2023)
- 10 Jul 2023 Preclinical trials in Gout in USA (PO) (Hinova Pharmaceuticals, pipeline July 2023)
- 10 Jul 2023 Preclinical trials in Hyperuricaemia (Combination therapy) in USA, China (PO) (Hinova Pharmaceuticals, pipeline July 2023)